Filter (Type enter to validate)
  Cat_Number Product name Supplier Quantity Price Tech More
ME1001Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, replaced by ME1003, 100 cases 100 coresUS Biomax266 ME1001 Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, replaced by ME1003, 100 cases 100 cores US Biomax 266
ASK
Publication
ME1004Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM, 100 cases 100 cores, replacing ME1003US Biomax314 ME1004 Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM, 100 cases 100 cores, replacing ME1003 US Biomax 314
ASK
Publication
ME1003Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replaced by ME1004US Biomax266 ME1003 Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replaced by ME1004 US Biomax 266
ASK
Publication
ME1004aMalignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replacing ME1004; ihc Anti-Actin confirmedUS Biomax296 ME1004a Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replacing ME1004; ihc Anti-Actin confirmed US Biomax 296
ASK
Publication
LC951Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases 95 coresUS Biomax456 LC951 Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases 95 cores US Biomax 456
ASK
Publication
ME1002Malignant melanoma and normal tissue array, 50 cases 100 coresUS Biomax266 ME1002 Malignant melanoma and normal tissue array, 50 cases 100 cores US Biomax 266
ASK
Publication
UV801Vulva malignant tumor tissue array, 39 cases 78 coresUS Biomax266 UV801 Vulva malignant tumor tissue array, 39 cases 78 cores US Biomax 266
ASK
Publication
CO951Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 coresUS Biomax456 CO951 Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 cores US Biomax 456
ASK
Publication
OV951Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases 95 cores,US Biomax456 OV951 Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases 95 cores, US Biomax 456
ASK
Publication
ME801Malignant melanoma tissue array, 80 cases 80 cores, replaced by ME804US Biomax231 ME801 Malignant melanoma tissue array, 80 cases 80 cores, replaced by ME804 US Biomax 231
ASK
Publication
ME2081Mid density malignant melanoma and normal tissue array, 104 cases 208 coresUS Biomax456 ME2081 Mid density malignant melanoma and normal tissue array, 104 cases 208 cores US Biomax 456
ASK
Publication
SO802Malignant fibrohistiocytoma tissue array, 80 cases 80 cores; ihc CD68 confirmedUS Biomax267 SO802 Malignant fibrohistiocytoma tissue array, 80 cases 80 cores; ihc CD68 confirmed US Biomax 267
ASK
Publication
BR952Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 coresUS Biomax456 BR952 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores US Biomax 456
ASK
Publication
KD951Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases 95 coresUS Biomax456 KD951 Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases 95 cores US Biomax 456
ASK
Publication
ME2082Malignant melanoma tissue array, including TNM and clinical stage, 208 cases 208 coresUS Biomax456 ME2082 Malignant melanoma tissue array, including TNM and clinical stage, 208 cases 208 cores US Biomax 456
ASK
Publication
ME242Low density malignant melanoma array, with stage and grade info, 24 cases 24 coresUS Biomax88 ME242 Low density malignant melanoma array, with stage and grade info, 24 cases 24 cores US Biomax 88
ASK
Publication
BC21014Skin malignant tumor tissue array, 78 cases 78 cores, replacing BC21011US Biomax231 BC21014 Skin malignant tumor tissue array, 78 cases 78 cores, replacing BC21011 US Biomax 231
ASK
Publication
BR954Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replacing BR953; ihc US Biomax429 BR954 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replacing BR953; ihc US Biomax 429
ASK
Publication
PR955Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR954US Biomax558 PR955 Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR954 US Biomax 558
ASK
Publication
BR953Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replacing BR952US Biomax456 BR953 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replacing BR952 US Biomax 456
ASK
Publication
PR954Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR955US Biomax456 PR954 Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR955 US Biomax 456
ASK
Publication
PR953Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR954US Biomax456 PR953 Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR954 US Biomax 456
ASK
Publication
BR951Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, to be replaced by BR95US Biomax456 BR951 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, to be replaced by BR95 US Biomax 456
ASK
Publication
ME482Malignant melanoma array with matched normal tissue control, stage and TNM, 48 cases 48 coresUS Biomax189 ME482 Malignant melanoma array with matched normal tissue control, stage and TNM, 48 cases 48 cores US Biomax 189
ASK
Publication
ME802Malignant melanoma with normal skin tissue array, 40 cases 80 cores, replacing BS38011US Biomax266 ME802 Malignant melanoma with normal skin tissue array, 40 cases 80 cores, replacing BS38011 US Biomax 266
ASK
Publication
CO952Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 cores, replacing CO951; ihc Anti-Cytokeratin (CK) confiUS Biomax429 CO952 Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 cores, replacing CO951; ihc Anti-Cytokeratin (CK) confi US Biomax 429
ASK
Publication
ME804Malignant melanoma tissue array, including TNM and clinical stage, 80 cases 80 cores, replacing ME801US Biomax266 ME804 Malignant melanoma tissue array, including TNM and clinical stage, 80 cases 80 cores, replacing ME801 US Biomax 266
ASK
Publication
PR956Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR955; ihc Anti-Actin confirUS Biomax487 PR956 Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR955; ihc Anti-Actin confir US Biomax 487
ASK
Publication
ME803Malignant melanoma array with matched and unmatched normal skin tissue control, with stage and TNM, 80 cases 80 coresUS Biomax266 ME803 Malignant melanoma array with matched and unmatched normal skin tissue control, with stage and TNM, 80 cases 80 cores US Biomax 266
ASK
Publication
OV602Tissue array of ovarian granulosa theca cell tumor (GTCT, malignant and benign) and cysts, 60 cases 60 coresUS Biomax231 OV602 Tissue array of ovarian granulosa theca cell tumor (GTCT, malignant and benign) and cysts, 60 cases 60 cores US Biomax 231
ASK
Publication
MTU951Multiple tumor tissue array covering 40 types of all the common benign, malignant and metastatic entities, 40 cases 95 coresUS Biomax225 MTU951 Multiple tumor tissue array covering 40 types of all the common benign, malignant and metastatic entities, 40 cases 95 cores US Biomax 225
ASK
Publication
ME2082aMalignant melanoma tissue array, including TNM and clinical stage, 208 cases 208 cores, replacing ME2082; ihc Anti-Actin confirmedUS Biomax429 ME2082a Malignant melanoma tissue array, including TNM and clinical stage, 208 cases 208 cores, replacing ME2082; ihc Anti-Actin confirmed US Biomax 429
ASK
Publication
T385aMalignant melanoma test tissue array, including TNM and clinical stage, 6 cases 24 cores, replacing T385; ihc Anti-Actin confirmedUS Biomax90 T385a Malignant melanoma test tissue array, including TNM and clinical stage, 6 cases 24 cores, replacing T385; ihc Anti-Actin confirmed US Biomax 90
ASK
Publication
BRC961Breast cancer array with normal and other non malignant breast tissues, non overlapping with BRC962, with AR ER PR Her 2(neu) IHC results, 48 cases 96 coresUS Biomax225 BRC961 Breast cancer array with normal and other non malignant breast tissues, non overlapping with BRC962, with AR ER PR Her 2(neu) IHC results, 48 cases 96 cores US Biomax 225
ASK
Publication
BR961Breast cancer array with normal and other non malignant breast tissues, with AR, ER, PR, Her 2 (neu) IHC results, 48 cases 96 cores, replaced by BR962US Biomax0 BR961 Breast cancer array with normal and other non malignant breast tissues, with AR, ER, PR, Her 2 (neu) IHC results, 48 cases 96 cores, replaced by BR962 US Biomax 0
ASK
Publication
T383Malignant melanoma test tissue array, with normal skin tissue, including TNM and pathology grade, 6 cases 24 coresUS Biomax88 T383 Malignant melanoma test tissue array, with normal skin tissue, including TNM and pathology grade, 6 cases 24 cores US Biomax 88
ASK
Publication
BR962Breast cancer array with normal and other non malignant breast tissues, with AR, ER, PR, Her 2 (neu) IHC results, 48 cases 96 cores, replacing BR961, BR701US Biomax231 BR962 Breast cancer array with normal and other non malignant breast tissues, with AR, ER, PR, Her 2 (neu) IHC results, 48 cases 96 cores, replacing BR961, BR701 US Biomax 231
ASK
Publication
T382Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 12 cases 24 coresUS Biomax88 T382 Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 12 cases 24 cores US Biomax 88
ASK
Publication
T388Malignant melanoma test tissue array (4x (2x3)array), including TNM and clinical stage, 6 cases 24 cores; ihc Anti-Actin confirmedUS Biomax90 T388 Malignant melanoma test tissue array (4x (2x3)array), including TNM and clinical stage, 6 cases 24 cores; ihc Anti-Actin confirmed US Biomax 90
ASK
Publication
T244Soft tissue malignant tumor tissue array, including TNM and clinical stage, 6 cases 24 cores; ihc Anti-Actin confirmedUS Biomax90 T244 Soft tissue malignant tumor tissue array, including TNM and clinical stage, 6 cases 24 cores; ihc Anti-Actin confirmed US Biomax 90
ASK
Publication
CR601Cervical carcinoma tissue array with cervical disease spectrum (normal, inflammation, CIN, malignant I III), 59 cases 60 cores, replaced by CR602US Biomax231 CR601 Cervical carcinoma tissue array with cervical disease spectrum (normal, inflammation, CIN, malignant I III), 59 cases 60 cores, replaced by CR602 US Biomax 231
ASK
Publication
T386Malignant melanoma test tissue array, with normal skin tissue, including TNM and clinical stage, 6 cases 24 cores, replacing T385US Biomax88 T386 Malignant melanoma test tissue array, with normal skin tissue, including TNM and clinical stage, 6 cases 24 cores, replacing T385 US Biomax 88
ASK
Publication
T381Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 6 cases 24 cores, replaced by T385US Biomax88 T381 Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 6 cases 24 cores, replaced by T385 US Biomax 88
ASK
Publication
T385Malignant melanoma test tissue array, with normal skin tissue as control, including TNM and clinical stage, 6 cases 24 cores, replaced by T386US Biomax88 T385 Malignant melanoma test tissue array, with normal skin tissue as control, including TNM and clinical stage, 6 cases 24 cores, replaced by T386 US Biomax 88
ASK
Publication
BC21011Skin malignant tumor tissue array, 78 cases 78 cores (squamous carcinoma, adenocarcinoma, basal cell carcinoma, sarcoma, melanoma), replaced by BC21014US Biomax231 BC21011 Skin malignant tumor tissue array, 78 cases 78 cores (squamous carcinoma, adenocarcinoma, basal cell carcinoma, sarcoma, melanoma), replaced by BC21014 US Biomax 231
ASK
Publication
ME803aMalignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 80 cases 80 cores, replacing ME803; ihc Anti-Actin confirmedUS Biomax296 ME803a Malignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 80 cases 80 cores, replacing ME803; ihc Anti-Actin confirmed US Biomax 296
ASK
Publication
ME241aMultiple malignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 12 cases 24 cores, replacing ME241; ihc Anti-Actin confirmedUS Biomax105 ME241a Multiple malignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 12 cases 24 cores, replacing ME241; ihc Anti-Actin confirmed US Biomax 105
ASK
Publication
IQ417Mouse Anti-Human Fibronectin Target Antigen Fibronectin Host Isotype Mouse IgG1 Application IHC (P); Immunohistochemical staining of matrix fibronectin in normal and malignant tissues on frozen secImunquest0.1ml (1mg/ml)492 IQ417 Mouse Anti-Human Fibronectin Target Antigen Fibronectin Host Isotype Mouse IgG1 Application IHC (P); Immunohistochemical staining of matrix fibronectin in normal and malignant tissues on frozen sec Imunquest 0.1ml (1mg/ml) 492
ASK
Publication
  Cat_Number Product name Supplier Quantity Price Tech More